ISS recommends shareholders ONLY vote on the BLUE Proxy in line with LabGold’s recommendationsISS states that the Dissident “has not presented a compelling case for any level of change, let alone a majority position” and advises shareholders to support all LabGold Nominees and long-term strategyDon’t delay. Vote BLUE today, well in advance of the voting deadline on February 20, 2026 at 11:00 a.m. (Toronto time)For assistance contact Kingsdale Advisors at 1-888-518-6813 (toll-free in North America), contactu ...

TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Company”) is pleased to announce that it has signed a Letter Agreement dated February 9, 2026 ( the “Letter Agreement”) to form a corporate joint venture (the “Joint Venture”) with Nemo Resources Inc. (“Nemo Resource Group” or “Nemo”) through a private exploration company, Elementary Minerals Inc. (“Elementary”). Elementary has acquired, through map staking, 127,100 hectares of mineral claims in the eas ...

BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable ...

Material Deficiencies in the Dissident’s Gold Proxy Have Been Identified by LabGoldThe Dissident’s Failure to Adhere to its Own Requisition May Affect the Validity of Their Gold ProxyShareholders are Urged to Vote ONLY on the BLUE Proxy or BLUE VIF to Ensure Votes Are Counted, and to Disregard any Gold or Other Proxy That They Receive From the Dissident Questions? Need Help Voting BLUE? Contact Kingsdale Advisors at 1-888-518-6813 (toll-free in North America), email contactus@kingsdaleadvisors.com, or visit ...

Material Deficiencies in the Dissident’s Gold Proxy Have Been Identified by LabGoldThe Dissident’s Failure to Adhere to its Own Requisition May Affect the Validity of Their Gold ProxyShareholders are Urged to Vote ONLY on the BLUE Proxy or BLUE VIF to Ensure Votes Are Counted, and to Disregard any Gold or Other Proxy That They Receive From the Dissident Questions? Need Help Voting BLUE? Contact Kingsdale Advisors at 1-888-518-6813 (toll-free in North America), email contactus@kingsdaleadvisors.com, or visit ...

Urges Shareholders to Act Today and Vote ONLY on the BLUE Proxy or VIF to Protect LabGold from a Self-Serving Dissident Who is Attempting to Take Control Without Paying Shareholders a PremiumQuestions? Need Help Voting BLUE? Contact Kingsdale Advisors at 1-888-518-6813 (toll-free in North America), email contactus@kingsdaleadvisors.com, or visit www.TheFutureofLAB.com TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Corporation”) today announced that ...

Financial Results - Standard BioTools Inc. reported preliminary financial results for the three months and fiscal year ended December 31, 2025, which are unaudited and subject to adjustments[4]. - The financial information provided does not represent a comprehensive statement of the Company's financial results and remains subject to completion of financial closing procedures[4]. Press Release - The press release detailing these results was issued on January 8, 2026, and is attached as Exhibit 99.1[4].

Core Viewpoint - Standard BioTools Inc. has completed the sale of SomaLogic to Illumina for $350 million upfront, with potential total proceeds of up to $425 million, marking a significant step in the company's strategic transformation and positioning for future growth [1][2]. Financial Details - The company received $350 million in upfront cash and is eligible for up to $75 million in near-term earnout payments based on performance metrics for 2025 and 2026 [2][12]. - Following the transaction, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million, which will support its inorganic growth strategy [4]. Strategic Implications - The sale is viewed as a major milestone in the company's strategic transformation, allowing it to pursue disciplined mergers and acquisitions to accelerate growth [2]. - Standard BioTools will receive a 2% royalty on net revenues from SOMAmer-based NGS library preparation kits for a duration of 10 years, along with a co-exclusive license for related intellectual property [3]. Operational Outlook - The company is on track to achieve positive adjusted EBITDA by 2026, indicating a focus on improving operational performance post-transaction [1].

Core Viewpoint - Labrador Gold Corp. is preparing for its Annual General and Special Meeting of Shareholders on February 24, 2026, where key matters including the election of directors and a proposed Change of Business will be discussed [1][2]. Meeting Details - The Meeting Materials include information on the election of LabGold directors, the proposed Change of Business to a Mining/Investment Issuer, and a name change related to the COB [2]. - Shareholders are encouraged to vote in favor of the management's resolutions and against the resolutions proposed by the Dissident, Coloured Ties Capital Inc. [3]. Strategic Direction - The Board is implementing a Change of Business strategy that integrates mining and investment opportunities to enhance liquidity, mitigate risk, and create multiple growth avenues [4]. - A thorough review of 29 resource-stage projects and 22 pre-resource projects over the past 18 months led to the conclusion that a hybrid model is the best approach for shareholder value [5]. Leadership and Expertise - The Corporation's nominees for the Board possess proven expertise in technical, operational, and capital markets, ensuring alignment with shareholder interests [6]. - Dr. Quinton Hennigh has been retained as a technical advisor, emphasizing a disciplined approach to capital deployment [7]. Financial Decisions - The Board has made strategic financial decisions, such as divesting the Kingsway Project to eliminate a $1 million monthly drilling commitment and monetizing shares of New Found Gold Corp. for immediate capital [9]. - These actions have optimized the treasury and positioned the Corporation for long-term growth and value creation [10]. Dissident Concerns - The Dissident, Coloured Ties, has a history of shareholder value destruction and conflicts of interest, raising concerns about their ability to manage the Corporation effectively [11][12]. - The Dissident's nominees lack the qualifications and capabilities necessary to execute the Corporation's strategic plan, with a documented history of poor performance in other ventures [12]. Meeting Participation - The Meeting will be held in person, and shareholders are encouraged to vote as soon as possible, with a voting deadline of February 20, 2026 [14][15].

Core Insights - Standard BioTools Inc. reported preliminary and unaudited revenue results for the full year 2025, expecting combined company revenue of approximately $185 million and revenue from continuing operations of approximately $85 million [1] - The fourth quarter 2025 is projected to have combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million [1] Financial Performance - The CEO of Standard BioTools, Michael Egholm, stated that the company's 2025 performance exceeded guidance and expectations for both combined and continuing operations [2] - The company is on a path toward profitability, having taken actions to streamline operations and improve cost structure, resulting in a leaner organization [2] Strategic Outlook - The sale of SomaLogic to Illumina is expected to close in the first half of 2026, with the company anticipating approximately $550 million in cash post-transaction [2] - The company aims to pursue disciplined mergers and acquisitions to build a diversified leader in life sciences, supported by an experienced team and a simplified operational footprint [2] Company Overview - Standard BioTools Inc. specializes in next-generation technologies that assist biomedical researchers in developing better medicines faster, focusing on areas such as oncology, immunology, and immunotherapy [4]